Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine

Journal of Infectious Diseases

Volumn 206, Issue 7, 2012, Pages 1059-1068

  Uzicanin, Amra ^a   Thompson, Mark ^a   Smith, Peter ^b   Chaves, Sandra S ^a   Foster, Lydia ^a   Dube, Nancy ^c   Graitcer, Samuel ^a   Jackson, Rebel ^a   Ferdinands, Jill ^a   Gargiullo, Paul ^a   Mills, Dora ^b   Monto, Arnold S ^d   Shay, David K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Maine Department of Health and Human Services   (United States)

^c Maine Department of Education   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADOLESCENT; ASTHMA; CASE CONTROL STUDY; CASE REPORT; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SINGLE DRUG DOSE; UNITED STATES;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MAINE; MALE; PANDEMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 84866087363     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis441     Document Type: Conference Paper

References (21)

1. Jhung MA, Swerdlow D, Olsen SJ, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011; 52(Suppl 1):S13-26.
2. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011; 52(Suppl 1):S75-82.
3. Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58(RR-10):1-8.
4. Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14:1108-10. (Pubitemid 26348827)
5. Lambkin R, Oxford JS, Biao L, Al-Jabri A, Fleming D. Rapid antibody response to influenza vaccination in "at risk" groups. Vaccine 2000; 18:2307-11. (Pubitemid 30136371)
6. Piedra PA, Gaglani MJ, Kozinetz CE, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-04 influenza type A (H3N2) outbreak provided immediate, direct and indirect protection in children. Pediatrics 2007; 120:e553-64.
7. Langholz B, Goldstein L. Risk set sampling in epidemiologic cohort studies. Statistical Science 1996; 11:35-53. (Pubitemid 126706118)
8. U.S. Department of Education. Common core of data\-school year 2008-2009. http://nces.ed.gov/ccd/bat/. Accessed 25 January 2011.
9. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza a vaccines for preventing pandemic influenza acute respiratory illness visits in 4 US communities. PLoS One 2011; 6:e23085.
10. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010; 363:2416-23.
11. Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203:32-9.
12. Hardelid P, Fleming DM, McMenamin J, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill 2011; 16:pii=19763.
13. Van Buynder PG, Dhaliwal JK, Van Buynder JL, et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010; 4:171-8.
14. Skowronski DM, Janjua NZ, De Serres G, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342: c7297.
15. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010; 28:7460-7.
16. Wichmann O, Stocker P, Poggensee G, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010; 15:19561.
17. Ross T, Zimmer S, Burke D, et al. Seroprevalence following the second wave of pandemic 2009 H1N1 Influenza. PLoS Curr 2010; 2:RRN1148.
18. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011; 204(Suppl 1):S133-49.
19. Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008; 197(Suppl 2):S82-9.
20. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008; 47:1458-67.
21. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62.